No more transplantation in CML?

Blood

Volumn 109, Issue 11, 2007, Pages 4592-

  Guilhot, François ^a  

^a Department of Anesthesiology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARAC PROTEIN; HYDROXYUREA; IMATINIB; INTERFERON;

ALLOGENEIC STEM CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DEATH; DRUG EFFICACY; HUMAN; NOTE; PRIORITY JOURNAL; RISK; SURVIVAL; TREATMENT OUTCOME;

EID: 34249668358     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-079459     Document Type: Note

References (5)

1. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
3. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303-2309.
4. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
5. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.